本文へ移動
cccskills
無料GitHub で公開

endo-assess-basal-settings-rate-testing

Evaluates basal insulin rates through basal rate testing across different time periods and adjusts as indicated. Triggered by clinician orders to 'Perform basal rate test to verify pump settings' or 'Check basal rates during periodic pump review'.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.0 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Assess basal settings via basal rate testing

STEP 1 — Gather Information

Collect recent CGM or SMBG glucose profiles (including overnight, pre‑meal, post‑meal), current basal rate schedule, recent hypoglycemia/hyperglycemia events, and confirm patient ability to safely fast for testing periods.
Action: Proceed to assess safety and eligibility for basal rate testing.

STEP 2 — Rule In / Rule Out

Determine if basal rate testing is safe: no recent severe hypoglycemia, patient can monitor glucose frequently, not pregnant or acutely ill, and has rapid‑acting carbohydrate available.

  • If unsafe → Rule out basal rate testing; pursue alternative assessment (e.g., review pump downloads, consider sensor‑guided adjustments).
  • If safe → Rule in basal rate testing; schedule test periods (typically overnight, pre‑breakfast, pre‑lunch, pre‑dinner).
    Action: Either rule out and document rationale, or rule in and prepare for testing.

STEP 3 — Classify or Stratify

Analyze glucose trends during each basal test period to classify pattern:

  • Stable (change ≤10 mg/dL) → no adjustment needed.
  • Hypoglycemic trend (fall >10 mg/dL) → basal too high.
  • Hyperglycemic trend (rise >10 mg/dL) → basal too low.
  • Dawn phenomenon (early‑morning rise) → consider increased basal overnight.
    Action: Identify basal adjustment direction and magnitude based on observed glucose drift.

STEP 4 — Decide

Adjust basal rates by 10‑20% for the identified periods (decrease for hypoglycemia, increase for hyperglycemia); if stable, hold current rate. Document changes, educate patient on signs of over/under‑basal, and plan follow‑up review.
Action: Implement basal rate adjustment and schedule reassessment in 1‑2 weeks.

Clinical Guardrails / Mimics / Pitfalls

Do not test during illness, alcohol use, or altered basal‑to‑bolus ratios; avoid >20% basal change per adjustment; ensure patient can treat hypoglycemia promptly; confirm basal rates remain physiologic (typically 40‑60% of total daily dose); beware of mistaking post‑prandial effects for basal needs.

Concrete Clinical Example

A 45‑year‑old with T1DM using CSII reports fasting glucose 180 mg/dL; overnight basal test shows a 30 mg/dL rise from 02:00–06:00; increase basal rate 15% during that window; follow‑up shows fasting glucose 130 mg/dL.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, Anne L. Peters et al., 2016, DOI: 10.1210/jc.2016-2534

TODO: consider adding scripts/calc.py for the endo-assess-basal-settings-rate-testing calculator

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する